サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788295

プラスミドDNA受託製造の世界市場

Plasmid DNA Contract Manufacturing

出版日
ページ情報
英文 170 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
プラスミドDNA受託製造の世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プラスミドDNA受託製造の世界市場は2030年までに13億米ドルに達する見込み

2024年に4億2,000万米ドルと推定されるプラスミドDNA受託製造の世界市場は、分析期間2024-2030年にCAGR 20.9%で成長し、2030年には13億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである細胞・遺伝子治療は、CAGR22.7％を記録し、分析期間終了時には8億8,500万米ドルに達すると予測されます。免疫療法分野の成長率は、分析期間のCAGRで17.0％と推定されます。

米国市場は1億1,040万米ドルと推定、中国はCAGR19.6％で成長予測

米国のプラスミドDNA受託製造市場は、2024年に1億1,040万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR19.6%で推移し、2030年には1億9,940万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.5％と17.9％と予測されています。欧州では、ドイツがCAGR約15.1%で成長すると予測されています。

世界のプラスミドDNA受託製造市場- 主要動向と促進要因のまとめ

プラスミドDNA受託製造市場は、遺伝子治療、mRNAワクチン、細胞ベースの免疫療法の需要拡大に牽引され、急速な拡大を遂げています。プラスミドDNA（pDNA）は、遺伝子医薬品、遺伝子編集、組換えタンパク質生産において重要な原料として機能し、バイオ医薬品開発において不可欠な要素となっています。バイオテクノロジー企業、製薬企業、研究機関が高度な遺伝子導入システムに注力する中、高品質でスケーラブルなプラスミドDNA生産へのニーズが急増しており、製造受託パートナーシップが増加しています。

市場の大きな動向は、大規模GMP（適正製造基準）プラスミドDNA生産施設の増加です。多くのバイオテクノロジー企業や新興企業は、臨床グレードのプラスミドDNAを製造する能力を社内に持たないため、開発・製造受託機関（CDMO）へのアウトソーシングにシフトしています。これらのCDMOは、細胞・遺伝子治療、ワクチン開発、CAR-T細胞療法製造などの用途向けに、高純度でエンドトキシンを含まず、規制に準拠したpDNAを提供しています。小規模の研究用プラスミドから商業規模のプラスミドDNA製造への移行は、バイオプロセスの最適化、自動化、上流／下流処理の革新への投資を加速させています。

もう一つの大きな推進力は、RNAベースの治療薬、特にmRNAワクチン生産におけるプラスミドDNAの役割の拡大です。COVID-19パンデミックは、プラスミドがmRNAワクチンの体外転写（IVT）用DNAテンプレートとして機能することから、スケーラブルなpDNA生産の重要性を浮き彫りにしました。がん免疫療法、個別化医療、タンパク質代替療法への新たな応用に伴い、プラスミドDNA受託製造業者は、需要の増加に対応するため、製造能力、ベクター設計能力、規制遵守の専門知識を拡大しています。

さらに、遺伝子治療製造における規制状況の進展と品質標準化は、プラスミドDNA受託製造の状況に影響を与えています。FDA、EMA、PMDAなどの規制機関は、遺伝子改変細胞療法やin vivo遺伝子導入システムにおいて、厳格なGMP要件、プラスミド安定性試験、汚染管理を重視しています。このためCDMOは、臨床応用のための高収率・高純度pDNA生産を確実にするため、品質管理（QC）、分析、高度な精製技術に投資しています。

技術革新はプラスミドDNA製造にどのような変化をもたらしているか？

プラスミドDNAの生産、精製、品質管理における技術的進歩は、受託製造の状況を再構築し、より高い収率、スケーラビリティの向上、汚染リスクの低減を可能にしています。業界は、従来の細菌発酵ベースのプラスミド生産から、効率と費用対効果を高める次世代バイオプロセス技術へと移行しつつあります。

最も革新的な技術革新のひとつは、大規模プラスミドDNA生産用の自動化された高密度発酵システムです。従来のプラスミド製造では、大腸菌による発酵が行われるが、これはプラスミド収率が低く、エンドトキシンレベルが高く、バッチ間のばらつきが生じやすいです。フェッドバッチ・バイオリアクターや灌流バイオリアクター、連続発酵、最適化されたベクター設計における最新の進歩は、培養1リットルあたりのプラスミド収量を高め、製造スループットを向上させ、製造コストを削減することを可能にしています。

もう一つの重要なブレークスルーは、従来のアルカリ溶解法に取って代わった、クロマトグラフィーをベースとした膜ろ過精製技術です。高度な陰イオン交換クロマトグラフィー（AEX）、タンジェンシャルフローろ過（TFF）、沈殿ベースの精製により、エンドトキシンレベルの低い高純度pDNAが可能になり、プラスミドが臨床および商業用途により適したものとなりました。これらの改善により、プロセスのスケーラビリティが向上し、精製のボトルネックが減少し、GMPグレードの製造における規制遵守が保証されます。

さらに、酵素および無細胞プラスミド増幅技術は、細菌発酵に代わる可能性のある技術として台頭してきています。無細胞転写／翻訳システムに基づく無細胞DNA合成プラットフォームは、細菌培養を行わずにプラスミドDNAを生産する有望なアプローチを提供し、細菌内毒素や宿主細胞汚染のリスクを排除します。これらの技術革新はプラスミドDNA製造に革命をもたらし、より迅速でスケーラブルな、個別化医療への応用に適したものとなると思われます。

さらに、AI主導のプロセス最適化とデジタルバイオマニュファクチャリングプラットフォームは、プラスミドDNA受託製造.AIを活用したバイオプロセス監視システム、予測分析、リアルタイム制御メカニズムは、CDMOが発酵パラメーターを最適化し、収量予測可能性を向上させ、生産の一貫性を高めるのに役立っています。AIと機械学習アルゴリズムは、ベクター工学、プラスミド設計の最適化、安定性予測にも活用され、新規遺伝子治療ベクターの開発スケジュールを加速しています。

市場力学と最終用途はどのように需要を形成しているか？

受託製造プラスミドDNAの需要は、遺伝子治療、ワクチン、遺伝子工学研究におけるアプリケーションの拡大によって形成されており、バイオテクノロジー企業、製薬会社、研究機関がアウトソーシング動向を牽引しています。

最大の応用分野のひとつは遺伝子治療で、プラスミドDNAはウイルスベクター生産（AAV、レンチウイルス、アデノウイルスなど）や直接非ウイルス遺伝子導入のための重要な原料として使用されています。CAR-TおよびTCR-T細胞療法、CRISPRベースの遺伝子編集、RNAベースの療法の急増により、GMPグレードの高コピープラスミドベクターの必要性が高まり、CDMOは生産能力を拡大する必要に迫られています。

もう一つの大きな成長分野はmRNAワクチンと治療開発です。プラスミドDNAはin vitro転写（IVT）用のDNAテンプレートとして機能するため、mRNA製造には不可欠です。製薬大手やバイオテクノロジー新興企業が感染症、がん免疫療法、自己免疫疾患向けの次世代mRNAワクチンに投資しているため、高収率でエンドトキシンを含まないpDNAの需要はかつてないほど高まっています。受託製造業者はIVT用にプラスミド調製を最適化し、高純度、安定性、GMPコンプライアンスを確保しています。

研究開発部門も重要な推進力となっており、学術機関、バイオテクノロジー新興企業、合成生物学企業が、遺伝子工学、合成生物学、前臨床研究のために研究グレードのプラスミドを必要としています。多くのCDMOは、初期段階の研究、カスタムプラスミドベクター、実現可能性研究に合わせた柔軟な少量生産のプラスミド生産サービスを提供しています。この需要は、バイオテクノロジー企業が前臨床から臨床規模の生産にシームレスに移行できるような、カスタマイズ可能でスケーラブルな受託製造モデルを加速させています。

さらに、規制遵守と製造の拡張性が受託製造戦略に影響を及ぼしています。プラスミドDNAが研究開発から商業化に移行するにつれて、CDMOはQuality-by-design（QbD）原則、規制に準拠したベクター工学、前臨床、臨床、商業サプライチェーンをサポートできる多層プラスミド生産プラットフォームを導入しています。ベクター設計、クローニング、発酵、精製、充填仕上げサービスを含むエンド・ツー・エンドのプラスミドDNA製造ソリューションへのシフトは、市場における主要な競合差別化要因になりつつあります。

プラスミドDNA受託製造市場の成長を促進する要因は何か？

プラスミドDNA受託製造市場の成長は、プラスミドDNAバイオプロセスの技術的進歩、遺伝子ベースの治療に対する需要の増加、GMP生産の拡張性、規制要件の進化など、いくつかの要因によって牽引されています。mRNAワクチン開発、ウイルスベクターベースの遺伝子治療、CRISPRゲノム編集の急増は、高品質のプラスミドDNAに対するかつてない需要を生み出しており、バイオテクノロジー企業や製薬会社は専門のCDMOへの委託を余儀なくされています。

個別化医療と再生療法の拡大も大きな推進力となっており、CAR-T、遺伝子編集、自己細胞療法の開発企業はカスタムプラスミドDNA製剤を必要としています。このため、迅速なスケーラビリティと生産期間の短縮を実現する、モジュール式の柔軟なプラスミド製造プラットフォームが登場しています。

市場成長を促進するもう一つの要因は、規制遵守と品質管理の強化です。FDAやEMAといった機関が遺伝子医薬品のGMPガイドラインを厳格化する中、CDMOはプラスミドDNAが臨床グレードの基準を満たしていることを保証するため、エンドトキシンフリーの精製、高度な分析、無菌性保証に注力しています。自動化されたAI主導のバイオ製造システムの開発は、生産効率、品質の一貫性、費用対効果をさらに高めています。

遺伝子治療、mRNAワクチン、合成生物学への応用が拡大し続ける中、プラスミドDNA受託製造業界は持続的な成長が見込まれます。ハイスループット生産、AIによる最適化、統合されたエンド・ツー・エンドのソリューションに投資する企業は、バイオ医薬品イノベーションの次の段階をリードする好位置につけると思われます。

セグメント

アプリケーション（細胞・遺伝子治療、免疫療法、その他）、治療領域（がん、感染症、自己免疫疾患、心血管疾患、その他）、エンドユーザー（製薬・バイオテクノロジー企業、研究機関）

調査対象企業の例

  • AGC Biologics
  • Akron Biotech
  • Aldevron（Danaher Corporation）
  • Asahi Kasei Corporation
  • BioCina
  • Bionova Scientific
  • Catalent Pharma Solutions
  • Charles River Laboratories
  • Delphi Genetics
  • Esco Aster PTE. LTD
  • Eurofins Genomics
  • JAFRAL Ltd.
  • Lonza Group
  • Luminous BioSciences, LLC
  • Nature Technology Corporation
  • PlasmidFactory GmbH & Co. KG
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies
  • VGXI, Inc.
  • VIVE Biotech

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32590

Global Plasmid DNA Contract Manufacturing Market to Reach US$1.3 Billion by 2030

The global market for Plasmid DNA Contract Manufacturing estimated at US$420.0 Million in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 20.9% over the analysis period 2024-2030. Cell & Gene Therapy, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$885.0 Million by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$110.4 Million While China is Forecast to Grow at 19.6% CAGR

The Plasmid DNA Contract Manufacturing market in the U.S. is estimated at US$110.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$199.4 Million by the year 2030 trailing a CAGR of 19.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.5% and 17.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

Global Plasmid DNA Contract Manufacturing Market - Key Trends & Drivers Summarized

The plasmid DNA contract manufacturing market is experiencing rapid expansion, driven by the growing demand for gene therapies, mRNA vaccines, and cell-based immunotherapies. Plasmid DNA (pDNA) serves as a critical raw material in genetic medicines, gene editing, and recombinant protein production, making it an essential component in biopharmaceutical development. With biotech companies, pharmaceutical firms, and research institutions focusing on advanced gene delivery systems, the need for high-quality, scalable plasmid DNA production has surged, leading to an increase in contract manufacturing partnerships.

A significant trend in the market is the rise of large-scale GMP (Good Manufacturing Practice) plasmid DNA production facilities. Many biotech firms and startups lack in-house capabilities to manufacture clinical-grade plasmid DNA, resulting in a shift toward outsourcing to contract development and manufacturing organizations (CDMOs). These CDMOs provide high-purity, endotoxin-free, and regulatory-compliant pDNA for applications in cell & gene therapy, vaccine development, and CAR-T cell therapy production. The transition from small-scale research-grade plasmids to commercial-scale plasmid DNA manufacturing is accelerating investments in bioprocess optimization, automation, and upstream/downstream processing innovations.

Another major driver is the expanding role of plasmid DNA in RNA-based therapeutics, particularly mRNA vaccine production. The COVID-19 pandemic highlighted the importance of scalable pDNA production, as plasmids serve as DNA templates for in vitro transcription (IVT) of mRNA vaccines. With emerging applications in cancer immunotherapy, personalized medicine, and protein replacement therapies, plasmid DNA contract manufacturers are expanding their manufacturing capacity, vector design capabilities, and regulatory compliance expertise to meet the increasing demand.

Additionally, regulatory advancements and quality standardization in gene therapy manufacturing are influencing the plasmid DNA contract manufacturing landscape. Regulatory agencies such as the FDA, EMA, and PMDA are emphasizing stringent GMP requirements, plasmid stability testing, and contamination control in gene-modified cell therapies and in vivo gene delivery systems. This has led to CDMOs investing in quality control (QC), analytics, and advanced purification techniques to ensure high-yield, high-purity pDNA production for clinical applications.

How Are Technological Innovations Transforming Plasmid DNA Manufacturing?

Technological advancements in plasmid DNA production, purification, and quality control are reshaping the contract manufacturing landscape, enabling higher yields, improved scalability, and reduced contamination risks. The industry is transitioning from traditional bacterial fermentation-based plasmid production to next-generation bioprocessing techniques that enhance efficiency and cost-effectiveness.

One of the most transformative innovations is automated, high-density fermentation systems for large-scale plasmid DNA production. Traditional plasmid manufacturing involves E. coli fermentation, which can lead to low plasmid yields, high endotoxin levels, and batch-to-batch variability. The latest advancements in fed-batch and perfusion bioreactors, continuous fermentation, and optimized vector design are allowing higher plasmid yield per liter of culture, improving manufacturing throughput and reducing production costs.

Another key breakthrough is chromatography-based and membrane filtration purification techniques, which have replaced conventional alkaline lysis methods. Advanced anion-exchange chromatography (AEX), tangential flow filtration (TFF), and precipitation-based purification enable high-purity pDNA with low endotoxin levels, making plasmids more suitable for clinical and commercial applications. These improvements enhance process scalability, reduce purification bottlenecks, and ensure regulatory compliance in GMP-grade manufacturing.

Additionally, enzymatic and cell-free plasmid amplification technologies are emerging as potential alternatives to bacterial fermentation. Cell-free DNA synthesis platforms, based on cell-free transcription/translation systems, offer a promising approach for producing plasmid DNA without bacterial culture, eliminating risks of bacterial endotoxins and host cell contamination. These innovations could revolutionize plasmid DNA manufacturing, making it faster, more scalable, and suitable for personalized medicine applications.

Moreover, AI-driven process optimization and digital biomanufacturing platforms are transforming plasmid DNA contract manufacturing. AI-powered bioprocess monitoring systems, predictive analytics, and real-time control mechanisms are helping CDMOs optimize fermentation parameters, improve yield predictability, and enhance production consistency. AI and machine learning algorithms are also being utilized in vector engineering, plasmid design optimization, and stability prediction, accelerating the development timeline for novel gene therapy vectors.

How Are Market Dynamics and End-Use Applications Shaping Demand?

The demand for contract-manufactured plasmid DNA is being shaped by expanding applications in gene therapies, vaccines, and genetic engineering research, with biotech firms, pharmaceutical companies, and research institutions driving outsourcing trends.

One of the largest application segments is gene therapy, where plasmid DNA is used as a critical raw material for viral vector production (such as AAV, lentivirus, and adenovirus) and direct non-viral gene delivery. The surge in CAR-T and TCR-T cell therapies, CRISPR-based gene editing, and RNA-based therapies has increased the need for GMP-grade, high-copy plasmid vectors, pushing CDMOs to scale up their production capacity.

Another major growth area is mRNA vaccine and therapeutic development. Plasmid DNA is essential in mRNA manufacturing, as it serves as a DNA template for in vitro transcription (IVT). With pharmaceutical giants and biotech startups investing in next-generation mRNA vaccines for infectious diseases, cancer immunotherapy, and autoimmune disorders, the demand for high-yield, endotoxin-free pDNA is at an all-time high. Contract manufacturers are optimizing plasmid preparation for IVT, ensuring high purity, stability, and GMP compliance.

The research and development sector is also a key driver, with academic institutions, biotech startups, and synthetic biology companies requiring research-grade plasmids for genetic engineering, synthetic biology, and preclinical studies. Many CDMOs offer flexible, small-batch plasmid production services tailored to early-stage research, custom plasmid vectors, and feasibility studies. This demand is accelerating customizable, scalable contract manufacturing models that allow biotech companies to transition seamlessly from preclinical to clinical-scale production.

Additionally, regulatory compliance and manufacturing scalability are influencing contract manufacturing strategies. As plasmid DNA moves from R&D to commercialization, CDMOs are implementing quality-by-design (QbD) principles, regulatory-compliant vector engineering, and multi-tiered plasmid production platforms that can support preclinical, clinical, and commercial supply chains. The shift toward end-to-end plasmid DNA manufacturing solutions, including vector design, cloning, fermentation, purification, and fill-finish services, is becoming a key competitive differentiator in the market.

What Factors Are Driving the Growth of the Plasmid DNA Contract Manufacturing Market?

The growth in the plasmid DNA contract manufacturing market is driven by several factors, including technological advancements in plasmid DNA bioprocessing, increasing demand for gene-based therapies, scalability of GMP production, and evolving regulatory requirements. The surge in mRNA vaccine development, viral vector-based gene therapies, and CRISPR genome editing is creating unprecedented demand for high-quality plasmid DNA, compelling biotech firms and pharma companies to outsource to specialized CDMOs.

The expansion of personalized medicine and regenerative therapies is also a major driver, with CAR-T, gene editing, and autologous cell therapy developers requiring custom plasmid DNA formulations. This has led to the emergence of modular, flexible plasmid manufacturing platforms that offer rapid scalability and reduced production timelines.

Another factor fueling market growth is regulatory compliance and quality control enhancements. With agencies such as the FDA and EMA tightening GMP guidelines for genetic medicines, CDMOs are focusing on endotoxin-free purification, advanced analytics, and sterility assurance to ensure plasmid DNA meets clinical-grade standards. The development of automated, AI-driven biomanufacturing systems is further enhancing production efficiency, quality consistency, and cost-effectiveness.

As gene therapy, mRNA vaccines, and synthetic biology applications continue to expand, the plasmid DNA contract manufacturing industry is expected to experience sustained growth. Companies that invest in high-throughput production, AI-driven optimization, and integrated end-to-end solutions will be well-positioned to lead the next phase of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Plasmid DNA Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Cell & Gene Therapy, Immunotherapy, Others); Therapeutic Area (Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Others); End-User (Pharma & Biotech Companies, Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AGC Biologics
  • Akron Biotech
  • Aldevron (Danaher Corporation)
  • Asahi Kasei Corporation
  • BioCina
  • Bionova Scientific
  • Catalent Pharma Solutions
  • Charles River Laboratories
  • Delphi Genetics
  • Esco Aster PTE. LTD
  • Eurofins Genomics
  • JAFRAL Ltd.
  • Lonza Group
  • Luminous BioSciences, LLC
  • Nature Technology Corporation
  • PlasmidFactory GmbH & Co. KG
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies
  • VGXI, Inc.
  • VIVE Biotech

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Plasmid DNA Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Gene Therapy, DNA Vaccines, and Cell Therapy Fuels Need for Scalable Plasmid DNA Manufacturing
    • Surge in mRNA and Nucleic Acid-Based Drug Development Strengthens Upstream Demand for Plasmid Supply
    • Limited Internal Capacity Among Biotech and Pharma Companies Drives Outsourcing to CDMOs Specializing in pDNA
    • Growth of ATMPs and Genetic Engineering Fuels Requirement for High-Purity, GMP-Grade Plasmid DNA
    • Expansion of Clinical Trials and IND Filings for Gene-Based Therapies Boosts Lot-Specific Plasmid Production
    • Technological Innovations in Fermentation, Purification, and Vector Design Enhance Yield and Quality of pDNA
    • Regulatory Focus on Vector Traceability and Safety Strengthens the Business Case for GMP-Compliant Plasmid Production
    • Increased Use of pDNA as a Raw Material for mRNA and Viral Vector Manufacturing Expands Service Scope
    • Investment in Cell and Gene Therapy Infrastructure Accelerates Demand for Integrated Plasmid Supply Chains
    • Emerging Markets and Biotech Hubs in Asia and Latin America Drive Globalization of pDNA Contract Manufacturing
    • Expansion of CRISPR and Genome Editing Research Fuels Lab-Scale and Clinical-Scale Plasmid DNA Needs
    • Capacity Constraints and Long Lead Times at Top-Tier CDMOs Create Opportunities for New Entrants and Niche Providers
    • Growth in Personalized Cancer Vaccines and Neoantigen Therapies Increases Small-Batch, High-Quality pDNA Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Plasmid DNA Contract Manufacturing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Plasmid DNA Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cell & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cell & Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • JAPAN
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • CHINA
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • EUROPE
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • FRANCE
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • GERMANY
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • UNITED KINGDOM
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Plasmid DNA Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Application - Cell & Gene Therapy, Immunotherapy and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Plasmid DNA Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy, Immunotherapy and Other Applications for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by End-user - Research Institutes and Pharma & Biotech Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Plasmid DNA Contract Manufacturing by End-user - Percentage Breakdown of Value Sales for Research Institutes and Pharma & Biotech Companies for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Plasmid DNA Contract Manufacturing by Therapeutic Area - Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Plasmid DNA Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases and Other Therapeutic Areas for the Years 2025 & 2030

IV. COMPETITION